Table 2.
Comparison of outcomes of paradoxical and nonparadoxical responders who received preemptive GCV therapy
| Parameter | Paradoxical respondersa | Nonparadoxical respondersb | P value |
|---|---|---|---|
| Median total duration [days (IQR)] of: | |||
| GCV use | 17 (13–20) | 13.5 (7–19) | 0.36 |
| Antigenemia clearance | 21 (21–21) | 14 (7–21) | <0.001 |
| Median posttreatment antigenemia level (IQR)c | 85 (23–268) | 1 (0–6) | <0.001 |
| No. (%) with: | |||
| Successful viral clearance | 20 (87) | 70 (95) | 0.35 |
| Secondary episode of CMV infection | 6 (26) | 17 (23) | 0.78 |
| Mean no. of days to onset of secondary episode after transplantation ± SD | 30.3 ± 33.9 | 52.2 ± 37.0 | 0.13 |
| CMV disease | |||
| Breakthrough disease | 4 (17) | 2 (3) | 0.03 |
| Late infection | 1 (4) | 3 (4) | >0.99 |
| Overall no. (%) of deaths | 8 (35) | 29 (39) | 0.70 |
| No. of CMV-related deaths | 0 | 0 |
a
Total n = 23.
b
Total n = 74.
c
Posttreatment levels are antigenemia levels measured after 7 days of GCV treatment.